Literature DB >> 34268483

Notch as an Immunologic Basis of Cancer Disparities.

Portia LaLiah Thomas1,2,3, Anil Shanker1,3,4,5.   

Abstract

Inter-individual differences due to racial/ethnic backgrounds may alter host immunity responsible for the cancer immunosurveillance and elimination, leading to disparate cancer incidence and relapse. One basis of disparity in tumor incidence, progression or therapeutic outcomes could lie in the components of Notch intercellular communication system, which provide instructive signals for a variety of pathways regulating cell commitment and differentiation including context-dependent lymphocyte polarization in tumor microenvironment. Notch signaling in hematopoietic cells is perturbed by tumor growth for its advantage, and there are indications that differences in Notch components could underlie poor cancer prognosis in certain populations. Here, we discuss the oncogenic and immunologic aspects of Notch, which should inform on cancer health disparities and therapeutic outcomes.

Entities:  

Keywords:  Cancer immunity; Health disparity; Immunosurveillance; Immunotherapy; Lymphocytes; Notch

Year:  2019        PMID: 34268483      PMCID: PMC8278364     

Source DB:  PubMed          Journal:  Cancer Health Disparities        ISSN: 2573-9530


  54 in total

1.  TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells.

Authors:  Tanapat Palaga; Lucio Miele; Todd E Golde; Barbara A Osborne
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

2.  Transient Notch signaling induces NK cell potential in Pax5-deficient pro-B cells.

Authors:  Sebastian Carotta; Jason Brady; Li Wu; Stephen L Nutt
Journal:  Eur J Immunol       Date:  2006-12       Impact factor: 5.532

3.  Th2 differentiation is unaffected by Jagged2 expression on dendritic cells.

Authors:  Connie M Krawczyk; Jie Sun; Edward J Pearce
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 4.  Notch signaling in the immune system.

Authors:  Freddy Radtke; Nicolas Fasnacht; H Robson Macdonald
Journal:  Immunity       Date:  2010-01-29       Impact factor: 31.745

5.  Differences in Breast Cancer Survival by Molecular Subtypes in the United States.

Authors:  Nadia Howlader; Kathleen A Cronin; Allison W Kurian; Rebecca Andridge
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-28       Impact factor: 4.254

6.  Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth.

Authors:  Yuhui Huang; Luping Lin; Anil Shanker; Anshu Malhotra; Li Yang; Mikhail M Dikov; David P Carbone
Journal:  Cancer Res       Date:  2011-08-08       Impact factor: 12.701

7.  Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling.

Authors:  Frank Cichocki; Martin Felices; Valarie McCullar; Steven R Presnell; Ahmad Al-Attar; Charles T Lutz; Jeffrey S Miller
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

8.  Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction.

Authors:  Mika Kijima; Takeshi Yamaguchi; Chieko Ishifune; Yoichi Maekawa; Akemi Koyanagi; Hideo Yagita; Shigeru Chiba; Kenji Kishihara; Mitsuo Shimada; Koji Yasutomo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

9.  Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.

Authors:  Rosa A Sierra; Jimena Trillo-Tinoco; Eslam Mohamed; Lolie Yu; Bhagelu R Achyut; Ali Arbab; Jennifer W Bradford; Barbara A Osborne; Lucio Miele; Paulo C Rodriguez
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

10.  KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway.

Authors:  Yitong Xu; Hongjiu Ren; Jun Jiang; Qiongzi Wang; Muli Wudu; Qingfu Zhang; Hongbo Su; Chenglong Wang; Lihong Jiang; Xueshan Qiu
Journal:  Cancer Sci       Date:  2018-03-25       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.